ClinicalTrials.gg

Program

4CMenB vaccine

Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.

In GlaxoSmithKline's pipeline, Recombinant protein and outer membrance vesicle vaccine. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.

Furthest: phase 4, since Apr 2, 200831 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis130 open or runningphase 3since Apr 2, 2008Feb 27, 2006none ahead
Pfizer90 open or runningphase 4since May 14, 2021Oct 11, 2006none ahead
GlaxoSmithKline71 open or runningphase 4since Feb 6, 2018Feb 14, 2014none ahead
Sanofi20 open or runningphase 3since Sep 4, 2019Sep 4, 2019none ahead
  • Named in GlaxoSmithKline’s own pipeline as Men B vaccine GSK3536829, phase 3, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Feb 27, 2006.

  1. Feb 14, 2014GlaxoSmithKline's first study: phase 3 study in Meningococcal InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT02106390 · 750 enrolled · Argentina, Mexico
  2. Jun 5, 2014Phase 3 study in Meningococcal InfectionsGlaxoSmithKline · NCT02173704 · 225 enrolled · Taiwan
  3. Aug 6, 2014Phase 2 study in Meningococcal InfectionsGlaxoSmithKline · NCT02212457 · 1,063 enrolled · United States, Finland, Poland
  4. Nov 20, 2014Phase 3 study in Meningitis, MeningococcalNovartis · NCT02305446 · 55 enrolled · Poland
  5. Apr 26, 2017Phase 3 study in Meningococcal VaccinePfizer · NCT03135834 · 1,610 enrolled · United States, Czechia, Finland and more
  6. Feb 6, 2018Phase 4 study in Meningitis, MeningococcalGlaxoSmithKline · NCT03493919 · 1,021 enrolled · Australia, Germany
  7. Sep 4, 2019Sanofi's first study: phase 3 study in Meningococcal Immunisation (Healthy Volunteers)New to SanofiSanofi · NCT04084769 · 570 enrolled · United States, Puerto Rico
  8. Jun 15, 2020Phase 3 study in Meningococcal VaccinePfizer · NCT04440163 · 2,431 enrolled · United States, Czechia, Denmark and more
  9. Aug 4, 2020Phase 3 study in Meningococcal InfectionsGlaxoSmithKline · NCT04502693 · 3,657 enrolled · United States, Australia, Canada and more
  10. Nov 20, 2020Phase 2 study in Meningococcal VaccinePfizer · NCT04645966 · 326 enrolled · Germany, Greece, Spain
  11. May 14, 2021Phase 4 study in Anemia, Sickle CellPfizer · NCT04893811 · 53 enrolled · Czechia, Poland, Turkey
  12. Oct 26, 2023Phase 2 study in Meningococcal ImmunisationSanofi · NCT06128733 · 1,215 enrolled · United States, Puerto Rico
  13. Oct 27, 2023Phase 4 study in Meningitis, MeningococcalGlaxoSmithKline · NCT06113198 · 50 enrolled · South Korea
  14. May 20, 2025Phase 3 study in MeningitisGlaxoSmithKline · NCT06995430 · 312 enrolled · Finland, Italy, Spain and more

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule

Studies

All 31 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06995430Meningitis · Finland, Italy, Spain and more3CompletedGlaxoSmithKlineDec 15, 2025312
NCT06113198Meningitis, Meningococcal · South Korea4Active, not recruitingGlaxoSmithKlineSep 7, 202650
NCT06128733Meningococcal Immunisation · United States, Puerto Rico2CompletedSanofiAug 27, 20251,215
NCT04893811Anemia, Sickle Cell · Czechia, Poland, Turkey4CompletedPfizerSep 6, 202353
NCT04645966Meningococcal Vaccine · Germany, Greece, Spain2TerminatedPfizerSep 15, 2022326
NCT04502693Meningococcal Infections · United States, Australia, Canada and more3CompletedGlaxoSmithKlineSep 13, 20223,657
NCT04440163Meningococcal Vaccine · United States, Czechia, Denmark and more3CompletedPfizerJul 24, 20222,431
NCT04084769Meningococcal Immunisation (Healthy Volunteers) · United States, Puerto Rico3CompletedSanofiSep 14, 2020570
NCT03493919Meningitis, Meningococcal · Australia, Germany4CompletedGlaxoSmithKlineMay 27, 20221,021
NCT03135834Meningococcal Vaccine · United States, Czechia, Finland and more3CompletedPfizerOct 25, 20221,610
NCT02305446Meningitis, Meningococcal · Poland3CompletedNovartisApr 201555
NCT02212457Meningococcal Infections · United States, Finland, Poland2CompletedGlaxoSmithKlineMay 22, 20151,063
NCT02173704Meningococcal Infections · Taiwan3CompletedGlaxoSmithKlineDec 25, 2015225
NCT02106390Meningococcal Infections · Argentina, Mexico3CompletedGlaxoSmithKlineOct 14, 2016750
NCT01911221Meningococcal Infections · Germany3CompletedNovartisApr 201413
NCT01830855Meningococcal Vaccine · United States, Canada, Czech Republic and more3CompletedPfizerApr 20153,596
NCT01768117Meningitis, Meningococcal · United States2CompletedPfizerFeb 201413
NCT01717638Meningococcal Infections · Czech Republic, Italy, Spain and more3CompletedNovartisSep 2013805
NCT01423084Meningococcal Infections · Australia, Canada3CompletedNovartisDec 2011344
NCT01352845Healthy · United States, Canada, Denmark and more3CompletedPfizerFeb 20153,301
NCT01323270Meningitis · Finland, Germany, Poland2CompletedPfizerOct 8, 2012753
NCT01214850N. Meningitidis Carriage · United Kingdom3CompletedNovartisJan 20122,968
NCT01139021Meningococcal Infections · Czech Republic, Finland3CompletedNovartisNov 2010508
NCT01026974Meningococcal Infections · United Kingdom2CompletedNovartisSep 2010120
NCT00944034Meningococcal Infections · Belgium, Czechia, Germany and more3CompletedNovartisAug 20111,588
NCT00937521Meningitis, Meningococcal · Argentina, Chile, Czech Republic and more2CompletedNovartisNov 20101,507
NCT00721396Meningococcal Infections · Belgium, Czech Republic, Germany and more2CompletedNovartisJul 20101,885
NCT00661713Meningococcal Infections · Chile3CompletedNovartisApr 20101,631
NCT00657709Meningitis, Meningococcal · Austria, Czechia, Finland and more3CompletedNovartisJan 20103,630
NCT00387725Healthy · Australia2CompletedPfizerJan 2008127
NCT00297817Meningococcal Infections · United States2CompletedNovartisApr 2007203

How it is read

Names in the registry

  • “rLP2086”, 11 entries
  • “rMenB+OMV NZ”, 9 entries
  • “Meningococcal B vaccine”, 6 entries
  • “rMenB+OMV NZ vaccine”, 3 entries
  • “Meningococcal group B vaccine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.